Molecular analysis revealed that the inhibition of HPK1 expression in CD4+ T cells of patients with SLE might be due to the loss of jumonji domain-containing protein D3 binding and increased histone H3 lysine 27 trimethylation enrichment at the HPK1 promoter, resulting in the overactivation of T cells and B cells [89]. The gene discussed is MAP4K1; the disease is systemic lupus erythematosus.